Posts tagged Arun Menawat
Profound Medical completes enrollment in TACT pivotal trial

Profound Medical (OTCQX:PRFMF; TSXV:PRN) has completed patient enrollment in the TACT pivotal study designed to further evaluate safety and efficacy of its TULSA-PRO medical device to ablate prostate tissue in patients with localized, organ-confined prostate cancer.

Read More
Profound Medical in $10-million bought deal, Q2 revenue up 62%

Profound Medical (OTCQB:PRFMF; TSXV:PRN) reported second quarter revenue of $957,139, compared to nil in the year ago quarter, but up 62% from $591,517 in the first quarter of 2017.

Read More
Profound completes Sonalleve acquisition from Royal Philips

Profound Medical (OTCQX:PRFMF; TSXV:PRN) has completed the acquisition of the Sonalleve MR-HIFU business from Royal Philips (NYSE:PHG; AEX:PHIA).

Read More
Profound Medical to expand collaboration with Royal Philips’, acquire Sonalleve unit

Profound Medical (OTCQX:PRFMF; TSXV:PRN) has agreed to expand an existing collaboration with Royal Philips (NYSE:PHG; AEX:PHIA) and acquire Philips’ Sonalleve MR-HIFU business, establishing Profound as a market leader in magnetic resonance (MR) ultrasound ablation therapy.

Read More
Profound Medical sells first TULSA-PRO in Finland

Profound Medical (OTCQX:PRFMF; TSXV:PRN) has successfully completed the first sale of a TULSA-PRO system in Finland to the Turku University Hospital, in collaboration with Royal Philips, who is working in partnership with Profound to commercialize the TULSA-PRO system in Europe.

Read More
Profound Medical to list on OTCQX

Shares of Profound Medical (TSX-V:PRN) will be eligible for trading on the OTCQX Best Market under the symbol, PRFMF, effective at the open on March 13.

Read More
Stereotaxis taps investor exec David Fischel as acting CEO

Stereotaxis (NASDAQ:STXS) announced a senior management change in a move designed to help re-establish the company’s growth trajectory.

Read More
Profound Medical names Arun Menawat as CEO

Profound Medical (TSX-V:PRN) appointed Arun Menawat as its new CEO.  Steven Plymale, the company’s current CEO, will transition to President and COO.

Dr. Menawat has been a member of Profound’s board since October 2014. Most recently, he was president and CEO of Novadaq Technologies, which pioneered the field of fluorescence imaging in the operating room.

Read More
Novadaq posts 52% jump in Q1 revenue

Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) has reported first quarter revenue of $17.7-million, up 52%, from $11.7-million a year ago.

Total direct sales in the quarter rose by $6.1-million, or 71%, and total partnered/international sales declined by $100,000, compared with the year earlier period.

Read More
Novadaq posts 54% jump in Q4 revenue

Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) has reported revenue of $20-million for the final quarter of 2015, up 54% from $13-million in the year earlier quarter, and up 18% from the third quarter of 2015.

Product sales increased by $9.3-million, or 95%, primarily due to an 89% increase in capital sales and a 107% increase in recurring revenue.

Read More
Novadaq Q4 revenue to jump about 54%

Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) has released preliminary unaudited revenue for the fourth quarter of 2015 of approximately $20-million, reflecting increases of about 54% from $13-million in the 2014 fourth quarter and 18% sequentially over $17-million in the third quarter last year.

For all of 2015, the company anticipates total revenues to be approximately $63.8-million, representing total year-over-year revenue growth of about 37%.

Read More